Fig. 2: Diverging antibody Fc profiles across ChAdOx1 nCoV-19 vaccinees who did or did not develop COVID-19.
a, Heatmap summarizing the SARS-COV-2 WT and beta (B.1.351)-specific IgG1, IgG3, IgA1 and IgM titers, as well as the ability of SARS-CoV-2-specific antibodies to bind to the low-affinity Fcγ-receptors (FcγR2A, Fcγ2B, Fcγ3a and Fcγ3b) across the vaccinees who did not (n = 140) or did develop COVID-19 (n = 30). Each column represents a distinct feature that was analyzed in the plasma and each row a different plasma sample. Titers and FcR data were first log(transformed) and z-scores are shown for comparison. b,c, Violin plot showing univariate comparisons of WT (b) and beta (c) SARS-CoV-2 S-specific Fc-antibody profiles between the groups. A Mann–Whitney U-test, with a correction for multiple comparison using the Benjamini–Hochberg method, was used to test for differences across the groups. d, A PCA applied to all samples and data, including vaccinees who did and did not develop COVID-19, to examine the impact of different demographic parameters on antibody profiles. In each panel, samples are colored based on sex, age, BMI and race, demonstrating limited effects of these demographic characteristics on shaping vaccine-induced humoral profiles. ***P < 0.001; **P < 0.01; *P < 0.05.
